Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $472,590.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 5,251 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total transaction of $472,590.00. Following the transaction, the chief operating officer owned 61,202 shares of the company’s stock, valued at approximately $5,508,180. This trade represents a 7.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kymera Therapeutics Stock Up 1.8%

NASDAQ KYMR opened at $87.71 on Friday. The firm has a market cap of $7.16 billion, a PE ratio of -23.83 and a beta of 2.28. The company has a 50 day moving average price of $84.06 and a 200 day moving average price of $74.56. Kymera Therapeutics, Inc. has a 52 week low of $25.50 and a 52 week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company’s revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.88) EPS. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on KYMR. Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Barclays upped their price target on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Finally, Stephens upped their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $118.90.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP increased its stake in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC increased its stake in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the period. Vanguard Group Inc. increased its stake in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares during the period. Finally, State Street Corp increased its stake in shares of Kymera Therapeutics by 9.4% in the fourth quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after acquiring an additional 190,383 shares during the period.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Several sell‑side analysts maintain bullish views and have raised price targets this quarter (Piper Sandler, Morgan Stanley, Stephens, BTIG), supporting demand for the shares and helping lift sentiment.
• Positive Sentiment: Small institutional increases were reported (several asset managers added modest stakes), which can provide incremental buying support in a thin float biotech. Institutional Activity
• Neutral Sentiment: Director Bruce Booth sold multiple tranches (April 14–15) totaling several thousand shares, but those sales were executed under a pre‑arranged Rule 10b5‑1 plan, which investors often view as scheduled liquidity rather than a change in insider conviction. SEC Form 4
• Negative Sentiment: COO Jeremy G. Chadwick sold a series of shares (total reported ~6,551 shares across April 14–15 at ~ $90 each) that reduced his stake; these transactions were disclosed without a 10b5‑1 designation, which can raise investor concern and likely pressured intraday trading. SEC Filing
• Negative Sentiment: Another insider, Noah Goodman, sold ~1,347 shares on April 14 (~$90/share) without a stated 10b5‑1 plan, further trimming insider ownership and adding to near‑term selling pressure. SEC Filing
• Negative Sentiment: Fundamentals remain a caution: the company missed Q4 EPS and revenue estimates in February (significant revenue shortfall year‑over‑year), which keeps the longer‑term risk profile elevated for a clinical‑stage biotech. Earnings & Key Metrics

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.